Liposarcoma, Myxoid clinical trials

The registry lists 40 studies for Liposarcoma, Myxoid across more than 10 countries. 12 are recruiting or about to start. 19 of them are mainly about Liposarcoma, Myxoid (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Liposarcoma, Myxoid studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting: 8
Terminated: 7
Completed: 7
Status unknown: 6
Active, not recruiting: 6
Withdrawn: 2

Phase

Phase 2: 21
Phase 1: 19
Early Phase 1: 2

Where

United States: 29
Netherlands: 8
France: 6
Canada: 6
Germany: 5
Spain: 4

Who runs them

USWM CT, LLC (4) · Fred Hutchinson Cancer Center (4) · Maria Sklodowska-Curie National Research Institute of Oncology (3) · Adaptimmune (3) · Salarius Pharmaceuticals, LLC (2) · National Cancer Institute (NCI) (2) · The Netherlands Cancer Institute (2) · M.D. Anderson Cancer Center (2)

What is being tested here

Drugs under test in Liposarcoma, Myxoid studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	All
Trabectedin	1	4
Seclidemstat	1	2
Brenetafusp	1	1
Mirdametinib	1	1
Palbociclib	1	1
Nogapendekin alfa inbakicept	1	1
Pazopanib	1	1
Selinexor	1	1
Letetresgene autoleucel	0	2
Autologous NY-ESO-1-specific CD8-positive T Lymphocytes	0	2

Coming up

0phase 3 studies under way

4studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4

Nov 2026Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 · M.D. Anderson Cancer Center
Jan 2027BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma · Michael Wagner, MD
Apr 2027START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Valo Therapeutics Oy
Nov 2027Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers · National Cancer Institute (NCI)

Who these studies take

Of the 8 Liposarcoma, Myxoid studies recruiting now, 5 (63%) set no upper age limit and 1 (13%) stop at 75 or younger. 2 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 8
Age	Women	Men
10	1 (13%)	1 (13%)
18	8 (100%)	8 (100%)
30	8 (100%)	8 (100%)
40	7 (88%)	7 (88%)
50	7 (88%)	7 (88%)
65	7 (88%)	7 (88%)
75	7 (88%)	7 (88%)
85	5 (63%)	5 (63%)

Across all 40 studies, recruiting or not: 8% stop at 75 or younger and 3% at 65; 18% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 40 of 40. search them.